1. Home
  2. SNGX vs NDRA Comparison

SNGX vs NDRA Comparison

Compare SNGX & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$0.36

Market Cap

7.6M

Sector

Health Care

ML Signal

N/A

Logo ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc.

N/A

Current Price

$4.75

Market Cap

8.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNGX
NDRA
Founded
1987
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
8.2M
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
SNGX
NDRA
Price
$0.36
$4.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 104.9K
13.7K
Earning Date
11-10-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
57.03
★ 84.32
EPS
★ N/A
N/A
Revenue
★ $119,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$2.96
52 Week High
$3.39
$6.95

Technical Indicators

Market Signals
Indicator
SNGX
NDRA
Relative Strength Index (RSI) 36.40 42.97
Support Level $0.32 $4.80
Resistance Level $0.82 $4.98
Average True Range (ATR) 0.02 0.31
MACD 0.01 -0.01
Stochastic Oscillator 64.02 58.92

Price Performance

Historical Comparison
SNGX
NDRA

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About NDRA ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.

Share on Social Networks: